Diabetes drug may help kidney transplant patients fight cell damage

NCT ID NCT04918407

Completed Disease control Sponsor: Shahid Beheshti University of Medical Sciences Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looked at whether adding empagliflozin (a diabetes drug) to insulin can reduce oxidative stress in people with type 2 diabetes who have had a kidney transplant. Forty patients were randomly assigned to receive either empagliflozin plus insulin or insulin alone for 90 days. Researchers measured various markers of oxidative stress in the blood to see if the combination therapy made a difference.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: empagliflozin
What this could lead to: If it works, this could point toward a way to reduce oxidative stress and improve outcomes for diabetic kidney transplant patients.
What could go wrong: This is a small, early-stage study with only 40 participants. It measures biological markers, not long-term health outcomes, so the real-world benefit is uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANT; COMPLICATIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KIDNEY TRANSPLANT; COMPLICATIONS

Contacts and locations

Locations

Labbafinezhd Hospital

Tehran, 166663423, Iran
SBMU

Tehran, 1666664321, Iran

More trials for these conditions

Other studies related to the condition(s) this trial covers.